Key result
Overexpression of GREM1 in aging human cardiac mesenchymal progenitor cells improved survival capacity and reduced cytotoxicity via the ERK/NRF2 antioxidant signal pathway.
Why the study?
Progenitor cell therapy efficacy is limited by cell aging and senescence, and GREM1's role in aging and senescence had never been investigated in human cardiac mesenchymal progenitor cells.
Answers are grounded in this paper and cite their sources.
Overexpression of GREM1 improves the survival capacity and reduces senescence of aging human cardiac mesenchymal progenitor cells via the ERK/NRF2 antioxidant pathway, suggesting a potential strategy to enhance cell-based therapies for myocardial repair.
Ischemic heart disease is the leading cause of mortality in the United States. Progenitor cell therapy can restore myocardial structure and function. However, its efficacy is severely limited by cell aging and senescence. Gremlin-1 (GREM1), a member of the bone morphogenetic protein antagonist family, has been implicated in cell proliferation and survival. However, GREM1's role in cell aging and senescence has never been investigated in human cardiac mesenchymal progenitor cells (hMPCs). Therefore, this study assessed the hypothesis that overexpression of GREM1 rejuvenates the cardiac regenerative potential of aging hMPCs to a youthful stage and therefore allows better capacity for myocardial repair. We recently reported that a subpopulation of hMPCs with low mitochondrial membrane potential can be sorted from right atrial appendage-derived cells in patients with cardiomyopathy and exhibit cardiac reparative capacity in a mouse model of myocardial infarction. In this study, lentiviral particles were used to overexpress GREM1 in these hMPCs. Protein and mRNA expression were assessed through Western blot and RT-qPCR. FACS analysis for Annexin V/PI staining and lactate dehydrogenase assay were used to assess cell survival. It was observed that cell aging and cell senescence led to a decrease in GREM1 expression. In addition, overexpression of GREM1 led to a decrease in expression of senescence genes. Overexpression of GREM1 led to no significant change in cell proliferation. However, GREM1 appeared to have an anti-apoptotic effect, with an increase in survival and decrease in cytotoxicity evident in GREM1-overexpressing hMPCs. Overexpressing GREM1 also induced cytoprotective properties by decreasing reactive oxidative species and mitochondrial membrane potential. This result was associated with increased expression of antioxidant proteins, such as SOD1 and catalase, and activation of the ERK/NRF2 survival signal pathway. Inhibition of ERK led to a decrease in GREM1-mediated rejuvenation in terms of cell survival, which suggests that an ERK-dependent pathway may be involved. Taken altogether, these results indicate that overexpression of GREM1 can allow aging hMPCs to adopt a more robust phenotype with improved survival capacity, which is associated with an activated ERK/NRF2 antioxidant signal pathway.
No takes yet. Share an insight, caveat, or question.
Kaur et al. (2023) studied Ischemic heart disease / Cardiomyopathy. Overexpression of GREM1 was evaluated on Cell survival and cytotoxicity. Overexpression of GREM1 in aging human cardiac mesenchymal progenitor cells improved survival capacity and reduced cytotoxicity via the ERK/NRF2 antioxidant signal pathway.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: